CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results-Reference-Cited by-同舟云学术

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

Published:2024-03-15 Issue:5 Volume:38 Page:963-968
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Schultz Liora M.,Jeyakumar Nikeshan,Kramer Anne Marijn^ORCID,Sahaf Bita,Srinagesh Hrishi,Shiraz Parveen,Agarwal Neha,Hamilton Mark,Erickson Courtney,Jacobs Ashley,Moon Jennifer,Baggott Christina,Arai Sally,Bharadwaj Sushma,Johnston Laura J.,Liedtke Michaela,Lowsky Robert,Meyer Everett,Negrin Robert,Rezvani Andrew,Shizuru Judy^ORCID,Sidana Surbhi^ORCID,Egeler Emily,Mavroukakis Sharon,Tunuguntla Ramya,Gkitsas-Long Nikolaos,Retherford Aidan,Brown Annie Kathleen,Gramstrap-Petersen Anne-Louise,Ibañez Raquel Martin,Feldman Steven A.,Miklos David B.^ORCID,Mackall Crystal L.^ORCID,Davis Kara L.,Frank Matthew,Ramakrishna Sneha,Muffly Lori^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02220-y.pdf

Reference26 articles.

1. Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21:116–31.

2. Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202–7.

3. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165–74.

4. Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964–9.

5. Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702–23.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology;Cells;2024-09-10

2. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study;The Lancet;2024-07